Skip to content

Contact +44 (0) 20 7060 7474 email us

Biotechnology

Stem Cell Markets

 

Publication Date June 2009
Publisher TriMark Publications
Product Type Report
Pages 103
ISBN Number TMRSTEM08-0701
Product Code TRI00063

Price

£2,245.00
approximately: $3,399 | €2,506

pdf

Buy Now

Order above formats by FAX

Order by Fax

Summary

A stem cell is an extraordinary type of cell that has the ability to self-renew for long periods of time and to differentiate into specialized cells under appropriate physiological or experimental conditions. Traditionally, stem cells have been classified as either embryonic, adult (tissue-specific or cord blood) stem cells. Recent understanding of stem cell biology may provide new approaches for the treatment of a number of diseases as well as tissue/organ injuries, including cardiovascular disease, neurological disease, musculoskeletal disease, diabetes and hematopoietic disorders. Stem cell fate is determined by both intrinsic regulators and the extra-cellular environment (niche), and their expansion and differentiation ex vivo are generally controlled by growing them in a specific configuration (monolayer or three-dimensional culture). This process, which is vital to enable stem cells to be used for therapeutic purposes, is called differentiation. Differentiation is a process involving unspecialized cells progressing to become specialized cells with restricted developmental potential. The purpose of this TriMark Publications report is to describe the specific market segments of the medical research space using stem cells for research and development (R&D) purposes. This study reviews all of the generally accepted analytical methods that are currently in use today for preparing and using stem cells. It examines the use of stem cells in developing new therapies for disease.

Contents

  • 1. Overview
    • 1.1 Statement of Report
    • 1.2 Scope of the Report
    • 1.3 Methodology
    • 1.4 Executive Summary
  • 2. Biology of Stem Cells
    • 2.1 Scope of this Chapter
    • 2.2 Basic Properties of Stem Cells and Their Classification
    • 2.3 Differentiation of Stem Cells
      • 2.3.1 Neural and Neuronal Differentiation
      • 2.3.2 Cardiomyogenic Differentiation of ESCs
      • 2.3.3 Differentiation of Mesenchymal Stem/Progenitor Cells
    • 2.4 Self-Renewal of Stem Cells
    • 2.5 Dedifferentiation and Nuclear Reprogramming
    • 2.6 Functional Proliferation of Adult Mature Cells
    • 2.7 Nanog Promotes Transfer of Pluripotency After Cell Fusion
    • 2.8 MicroRNAs in Stem Cell Development
    • 2.9 Stem Cell Therapy
  • 3. Market Analysis of the Stem Cell Space
    • 3.1 Scope of this Chapter
    • 3.2 Overall Market Opportunity and Segmentation of the Total Stem Cell Marketplace
    • 3.3 Potential Stem Cell Commercial Applications
      • 3.3.1 Cord Blood Stem Cells and Cord Blood Stem Cell Banking: Current Market Environment and Opportunity
    • 3.4 Results of Primary Market Survey to Characterize Qualitative and Quantitative Trends in the Stem Cells Space
      • 3.4.1 Characteristics of the Respondent Pool
      • 3.4.2 Utilization of the Different Classes of Stem Cells
      • 3.4.3 Quantitative Metrics of the Stem Cell Research Marketplace: Number of Experiments Performed in Research
      • 3.4.4 Evolution of Research Activities with Different Types of Stem Cells: Current Usage Trends and Usage in 12 to 18 Months
      • 3.4.5 Types of Stem Cell Research Activities Performed by the End-User Community
      • 3.4.6 Challenges Facing Stem Cell Researchers
      • 3.4.7 Market Drivers and Research Questions Being Addressed in the Stem Cell Space
      • 3.4.8 Summary of Challenges and Opportunities in the Stem Cell Space Based on TriMark?s Analysis
      • 3.4.9 Unmet Product Needs in the Stem Cell Research Space and Licensing/IP Constraints
    • 3.5 Competitive Landscape of the Stem Cell Marketplace
      • 3.5.1 SWOT Analysis of the Major Stem Cell Market Segments
    • 3.6 Market Size and Forecasts
  • 4. Worldwide Landscape of Stem Cell Research
    • 4.1 Scope of this Chapter
    • 4.2 Global Embryonic Stem Cell Research
      • 4.2.1 Top Research Institutions Worldwide in the Stem Cells Space and Global ?Hot Spots? for Research and Therapeutics
    • 4.3 Stem Cell Research in the U.S
      • 4.3.1 Proposition 71 in the State of California
    • 4.4 Intellectual Property (IP) Landscape Surrounding Stem Cells
    • 4.5 Who Will Finance Stem Cell Research?
      • 4.5.1 U.S. Government Policy on Stem Cell Research
      • 4.5.2 Current Federal Policy
        • 4.5.2.1 Moral Issues Affecting Pre-Obama Federal Policy
        • 4.5.2.2 Significance and Requirements for Federal Funding
        • 4.5.2.3 Draft Guidelines for the new NIH stem cell funding policy
      • 4.5.3 International Law
        • 4.5.3.1 Australia
        • 4.5.3.2 U.K
        • 4.5.3.3 Canada
        • 4.5.3.4 China
        • 4.5.3.5 Germany
        • 4.5.3.6 Switzerland
        • 4.5.3.7 Japan
        • 4.5.3.8 Israel
        • 4.5.3.9 Singapore
      • 4.5.4 Technological and Economical Disadvantages for the U.S
  • 5. Therapeutic Areas and Research Programs in the Stem Cell Space
    • 5.1 Scope of this Chapter
    • 5.2 Therapeutic and Other Markets Addressed by Stem Cells
      • 5.2.1 Hematopoietic Stem Cells (HSCs)
      • 5.2.2 Stem Cell Therapeutics for Cardiac and Ischemic Diseases
      • 5.2.3 Stem Cell Therapeutics for Type I Diabetes
      • 5.2.4 Stem Cell Therapeutics for Orthopedic Diseases
      • 5.2.5 Stem Cell Therapeutics for Neurological Diseases
    • 5.3 Off-the-Shelf Stem Cells Being Developed
  • 6. Company Profiles
    • 6.1 Aastrom Biosciences
    • 6.2 Advanced Cell Technology
    • 6.3 BioE
    • 6.4 Bioheart
    • 6.5 Cryo-Cell International
    • 6.6 ES Cell International
    • 6.7 Gamida Cell
    • 6.8 GenVec
    • 6.9 Geron
    • 6.10 NeuroGeneration
    • 6.11 Osiris Therapeutics
    • 6.12 Pluristem Therapeutics
    • 6.13 ReNeuron
    • 6.14 StemCells, Inc
    • 6.15 Titan Pharmaceuticals
    • 6.16 ViaCell (now PerkinElmer)
  • Appendices
    • Appendix 1. Glossary of Terms in Stem Cell Biology 101?
  • List of Figures
    • Figure 2.1: Derivation of Embryonic Stem Cells (ESCs) from the Inner Cell Mass of Blastocysts
    • Figure 2.2: Classification of Stem Cells: Embryonic Stem Cells Versus Adult Stem Cells
    • Figure 2.3: Somatic Cell Nuclear Transfer (SCNT)
    • Figure 3.1: Segmentation of the Stem Cell Marketplace Based Upon Commercial Offerings?Products and Services
    • Figure 3.2: Geographical Breakout of Stem Cell End-User Survey Respondents
    • Figure 3.3: Affiliation (Pharma, Biotech, Academic/University) of Stem Cell End-User Survey Respondents
    • Figure 3.4: Survey Respondents That Are Studying Stem Cells or Using Stem Cells in Their Research
    • Figure 3.5: Length of Time Survey Respondent Pool Has Been Studying Stem Cells or Using Stem Cells in Its Research Activities
    • Figure 3.6: Utilization/Research with Different Stem Cell Types
    • Figure 3.7: Number of Experiments Involving Stem Cells Conducted Per Week
    • Figure 3.8: Differences with Respect to Usage of Stem Cell Types
    • Figure 3.9: Research Dollars Spent Monthly on Research/Studies with Different Stem Cell Types
    • Figure 3.10: Growth of Research Spending in Various Segments of the Stem Cells Space (Defined by Stem Cell Type)
    • Figure 3.11: Growth in End-User Utilization of Various Stem Cell Types
    • Figure 3.12: Breakout of the Stem Cell Research Market: Current Research Efforts with Different Types of Stem Cells
    • Figure 3.13: Breakout of the Stem Cell Research Market: Research Efforts with Different Types of Stem Cells in 12 to 18 Months
    • Figure 3.14: Broad Classification of Research Activities Being Performed with Stem Cells by Researchers
    • Figure 3.15: Current End-User Utilization Category for Adult Stem Cells (ASCs)
    • Figure 3.16: Current End-User Utilization Category for Human Embryonic Stem Cells (hESCs)
    • Figure 3.17: Current End-User Utilization Category for Human Cord Blood Stem Cells
    • Figure 3.18: Current End-User Utilization Category for Animal Stem Cells
    • Figure 3.19: Current End-User Utilization Category for Cancer Stem Cells
    • Figure 3.20: Challenges in the Study or Utilization of Adult Stem Cells (ASCs)
    • Figure 3.21: Challenges in the Study or Utilization of Human Embryonic Stem Cells (hESCs)
    • Figure 3.22: Challenges in the Study or Utilization of Human Cord Blood Stem Cells
    • Figure 3.23: Challenges in the Study or Utilization of Animal Stem Cells
    • Figure 3.24: Challenges in the Study or Utilization of Cancer Stem Cells
    • Figure 3.25: Top Unmet Needs in Commercial Products in the Stem Cell Research Space
    • Figure 3.26: U.S. Stem Cell Therapy Market Sales, 2005-2016
    • Figure 4.1: Stem Cell Research Worldwide 61?
  • List of Tables
    • Table 2.1: The Different Types of Stem Cells and Their Properties
    • Table 2.2: Adult Stem Cell (ASC) Differentiation Properties
    • Table 3.1: Characteristics of Different Stem Cell Types and Associated Market Opportunities
    • Table 3.2: Segmentation of the Stem Cell Market by Type/Lineage of Stem Cells
    • Table 3.3: Selected Cord Blood Banks in the U.S
    • Table 3.4: Selected Companies in the Cord Blood Stem Cell Technology and Therapeutics Development Space
    • Table 3.5: Breakout of the Stem Cell Research Market: Current Research Efforts with Different Types of Stem Cells
    • Table 3.6: Breakout of the Stem Cell Research Market: Research Efforts with Different Types of Stem Cells in 12 to 18 Months
    • Table 3.7: Market Share of Companies/Institutions Offering Different Stem Cells to Researchers
    • Table 3.8: Market Share of Companies/Institutions Offering Reagents for Stem Cell Research
    • Table 3.9: The U.S. Stem Cell Therapy Market Forecast, 2005-2016
    • Table 4.1: Major Milestones in Stem Cell Research and Associated Timeline, 1981-2009
    • Table 4.2: Selected Stem Cell Hot Spots Worldwide Administering Non-FDA Approved Stem Cell Therapeutic Regimens
    • Table 4.3: NIH Funding of Stem Cell Research in the U.S., 2004-2009
    • Table 4.4: Snapshot of the Current Key Stem Cell Patents
    • Table 5.1: Estimate of Potential Market Opportunity for Stem Cell-based Therapeutics
    • Table 5.2: Autologous Versus Allogeneic Cell Therapy
    • Table 5.3: Diseases Treated with HSC Transplantation Today
    • Table 5.4: HSC Sources and Their Properties
    • Table 5.5: Stem Cell Therapeutics for Hematological Diseases in Development
    • Table 5.6: Stem Cell-based Therapeutics for Cardiac and Ischemic Diseases in Development
    • Table 5.7: Stem Cell-based Therapeutics for Vascular Diseases in Development
    • Table 5.8: Stem Cell Therapeutics for Type I Diabetes in Development
    • Table 5.9: Stem Cell Therapeutics for Orthopedic Disease in Development
    • Table 5.10: Stem Cell Therapeutics for Neurological Disease in Development
    • Table 5.11: Segmentation of the Allogeneic Cell Therapy Market